Acute Hepatic Porphyria (AHP)

Acute hepatic porphyria

Acute hepatic porphyrias (AHPs) are a group of rare genetic disorders that result in enzyme deficiencies, disrupting the normal heme biosynthetic pathway. This can cause accumulation the neurotoxic porphyrin precursors, δ-ALA and PBG.

Common questions about AHP

How common is AHP?

Acute intermittent porphyria is the most common type of AHP, with an estimated prevalence of one in 100,000.

Who is most at risk?

Women of childbearing age have the highest prevalence of AHP.

Which conditions can be confused with AHP?

AHPs are frequently mistaken for other diseases, including infections, inflammatory bowel disease, acute cholecystitis, appendicitis, pancreatitis and intestinal occlusion. Diagnosis of AHPs is frequently delayed, with an average of 15 years from onset of symptoms to diagnosis.

How does AHP affect people with the disorder?

AHPs are associated with acute attacks characterised by symptoms including severe, diffuse abdominal pain, nausea, weakness and constipation. In some cases, AHP acute attacks can be fatal.

Is there a treatment?

There is no cure for AHP, but there are ways to manage its symptoms. Symptom management may include pain medication and glucose supplementation. Hospital stays may be required in the case of severe attacks.

Industry-funded resources